[Newsdesk] Research brief

Summary: US researchers have identified four compounds with in-vitro potency against severe respiratory syndrome coronavirus 2 (SARS-CoV-2). X-ray crystallography and 3D modelling of molecular docking showed that the compounds targeted the virus’ main protease, Mpro, which is essential in host-cell entry and viral replication. The four compounds, identified after screening more than 50 proteases, included boceprevir (an FDA-approved hepatitis C drug) and GC-376, a veterinary drug under investigation for a feline coronavirus.

Source: The Lancet Infectious Diseases

Read More

Be the first to comment

Leave a Reply

Your email address will not be published.


*